

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See instruction 10.

1. Name and Address of Reporting Person* <u>Myles David C.</u> <hr/> (Last) (First) (Middle) <u>C/O OLEMA PHARMACEUTICALS, INC.</u> <u>780 BRANNAN ST</u> <hr/> (Street) <u>SAN FRANCISCO CA 94103</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Olema Pharmaceuticals, Inc. [OLMA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>CH. DISCOV. & NON-CLIN DEV OFF</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/12/2026</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/12/2026		S		10,000	D	\$28.34 ⁽¹⁾	144,846	I	See Footnote ⁽²⁾
Common Stock	01/13/2026		M		50,000	A	\$4.87	592,761 ⁽³⁾	D	
Common Stock	01/13/2026		S		49,800	D	\$27.6 ⁽⁴⁾	542,961	D	
Common Stock	01/13/2026		S		200	D	\$28.49	542,761	D	
Common Stock	01/14/2026		M		50,000	A	\$4.87	592,761	D	
Common Stock	01/14/2026		S		14,997	D	\$28.6 ⁽⁵⁾	577,764	D	
Common Stock	01/14/2026		S		35,003	D	\$28.99 ⁽⁶⁾	542,761	D	
Common Stock								12,831	I	See Footnote ⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$4.87	01/13/2026		M			50,000	(8)	01/31/2033	Common Stock	50,000	\$0	100,000	D	
Stock Option (Right to Buy)	\$4.87	01/14/2026		M			50,000	(9)	01/31/2033	Common Stock	50,000	\$0	50,000	D	

Explanation of Responses:

- The weighted average sale price for the transaction reported was \$28.34, and the range of prices were between \$28.07 and \$28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The shares are held by Myles Properties Inc., of which the Reporting Person is President.
- On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4.
- The weighted average purchase price for the transaction reported was \$27.60, and the range of prices were between \$27.35 and \$28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.
- The weighted average sale price for the transaction reported was \$28.60, and the range of prices was between \$27.80 and \$28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was \$28.99, and the range of prices was between \$28.80 and \$29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

7. The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.

8. 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

9. 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

/s/ Shane Kovacs, Attorney-in-
Fact 01/14/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.